Aurobindo Pharma Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurobindo Pharma Limited
Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?
CEO Ying Huang talked about the biotech’s plans for CAR-T therapies after its J&J-partnered program.
Aurobindo says a new logistics and industrial site opened in France by local subsidiary Laboratoire Arrow will support the firm’s growth plans in the French market.
Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Acrotech Biopharma, LLC
- Glaxo (India)
- TL Biopharmaceutical AG.